SCHEMBL24253941

SCHEMBL24253941

COc1nc(Cl)cc(-n2cccn2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 3/20 0.42
NOTUM Q6P988 1/20 0.38
ADORA2A P29274 5/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ADORA1 P30542 2/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
G6PD P11413 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 3/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20416864 0.76 KDM4E (0.46) KDM4EALDH1A1NOTUMADORA2AADORA1
SCHEMBL19805972 0.75 KMT2A (0.49) KDM4EALDH1A1NOTUMADORA2ANPC1
SCHEMBL29976158 0.75 KMT2A (0.49) KDM4EALDH1A1NOTUMADORA2ANPC1
SCHEMBL19132920 0.74 KDM4E (0.44) KDM4EALDH1A1ADORA2ANPC1RAB9A
SCHEMBL19687410 0.73 KDM4E (0.40) KDM4EALDH1A1NOTUMADORA2AADORA1
SCHEMBL232399 0.71 MAPT (0.41) ALDH1A1MEN1MAPTKMT2ALMNA
SCHEMBL19687409 0.69 ADORA2A (0.61) KDM4EADORA2AMEN1MAPTKMT2A
SCHEMBL16506222 0.69 NOTUM (0.57) KDM4EALDH1A1NOTUMADORA2ANPC1
SCHEMBL21144033 0.69 ADORA2A (0.54) KDM4EALDH1A1NOTUMADORA2ANPC1
SCHEMBL10027698 0.69 ALDH1A1 (0.59) KDM4EALDH1A1NOTUMADORA2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092042-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-03-20 US disclosed
US-12157737-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2024-12-03 US disclosed
US-20240043425-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2024-02-08 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
EP-4196478-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2023-06-21 EP disclosed
CN-116157404-A Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof 诺华股份有限公司 2023-05-23 CN disclosed
WO-2022034529-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2022-02-17 WO disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157737-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 KDM4E 2714/4885ALDH1A1 323/4885NOTUM 3732/4885
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 KDM4E 2714/4885ALDH1A1 323/4885NOTUM 3732/4885
US-20240043425-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 KDM4E 2714/4885ALDH1A1 323/4885NOTUM 3732/4885
US-20250092042-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, PKD1, PKD2 KDM4E 2744/4885ALDH1A1 200/4885NOTUM 3519/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 KDM4E 2714/4885ALDH1A1 323/4885NOTUM 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.